Biorce is thrilled to announce a significant funding milestone by raising $5,000,000, marking a pivotal moment in our journey to revolutionize clinical trial design. We are the embodiment of bold thinking confronting clinical trial complexity, and this fresh capital injection underscores our commitment to advancing innovation in a highly regulated space. Our flagship solution, Jarvis by Biorce, stands as the world’s first AI protocol assistant tailored specifically for clinical research. Jarvis is powered by insights gleaned from over 500,000 global studies, providing proven endpoint suggestions, real-time feasibility checks, regulatory alignment, and actionable, evidence-based insights—all designed to support and enhance expert decision-making.
This funding will enable us to further invest in our cutting-edge technology, scale our operations, and deepen our market outreach among biotech firms, pharmaceutical companies, and Contract Research Organizations (CROs). By harnessing modern AI capabilities, we help our partners reduce unnecessary waste and administrative burdens, minimize costly protocol amendments, and accelerate the trial process without sacrificing accuracy, compliance, or quality. Our mission is clear: to empower clinical teams to move faster while remaining meticulous and risk-averse. Each innovation is a step towards smarter, more efficient trials that ultimately lead to safer and more effective patient care. With this investment, Biorce is not only reinforcing its commitment to transforming clinical trial protocols, but also ensuring that every trial we support is a testament to enhanced diligence and streamlined processes—one protocol at a time, one patient at a time.
